Get the Stockscreener App
3.34
0.74%
0.03
Bioatla Inc stock is traded at $3.34, with a volume of 2,435.
It is up +0.74% in the last 24 hours and down -7.74% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
See More
Previous Close:
$3.37
Open:
$3.34
24h Volume:
2,435
Relative Volume:
0.05
Market Cap:
$5.55M
Revenue:
$2.00M
Net Income/Loss:
$-50.62M
P/E Ratio:
-0.0799
EPS:
-41.8255
Net Cash Flow:
$-37.11M
1W Performance:
-8.24%
1M Performance:
-7.74%
6M Performance:
-79.12%
1Y Performance:
-80.86%
1-Day Range:
$3.33
$3.415
1-Week Range:
$3.2006
$3.855
52-Week Range:
$3.12
$71.50
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
3.3416 | 5.59M | 2.00M | -50.62M | -37.11M | -41.83 |
VRTX
Vertex Pharmaceuticals Inc
|
485.15 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
674.16 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
907.15 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.28 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.62 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioAtla, Inc. Revenue Breakdown – NASDAQ:BCAB - TradingView
TradingKey - TradingKey
BCAB|Bioatla Inc|Price:3.350|Chg%:-0.110 - TradingKey
BCAB|Bioatla Inc|Price:3.481|Chg%:+0.091 - TradingKey
Bioatla Inc (BCAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioAtla Company Profile & Introduction - Moomoo
BioAtla, Inc. 8-K SEC Filing: Company Profile, Key Data, and Stock Information for July 2026 - Minichart
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Provides OptimismEarnings Miss Streak - DonanımHaber
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrower Net Loss Surpasses Expectations as Clinical Pipeline ProgressesBasic EPS Analysis - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock DeclinesTax Rate Impact - dars.gov.et
BioAtla Inc. (BCAB) Surges Nearly 6% as Shares Test Key Resistance LevelStraddle Setup - dars.gov.et
BCAB Q4 2025 Earnings: Narrowing Losses Beat Street Estimates as Stock Rises 4%Net Income Trends - DonanımHaber
Price to sales forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) - TradingView
BCAB Forecast — Price Target — Prediction for 2027 - TradingView
BioAtla: BioAtla, Inc.Reverse Split Option Symbol: BCAB New Symbol: BCAB1 - Moomoo
BioAtla Inc. (BCAB) Jumps Over 7% as Biotech Momentum BuildsValue Area Low - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Surprises; Shares Edge HigherEarnings Surprise Report - dars.gov.et
BioAtla (BCAB) Q4 2025 Earnings: Narrowed Loss Beats Expectations as Stock AdvancesEarnings Expansion Phase - dars.gov.et
Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioatla Inc (BCAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bioatla Inc (BCAB) Institutional Confidence - TradingKey
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrowed Loss and Positive Surprise Boost Investor Sentiment - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Consistency Score - newsline.com
BCAB Q4 2025 Earnings: Narrower Loss Surprises, Shares RiseLow Estimate Range - newsline.com
BioAtla Inc. (BCAB) Slips 2.5% as Shares Test Key Support ZoneBearish Pattern Stocks - newsline.com
BioAtla (BCAB) Slips 4.58% as Stock Nears Critical Support LevelTotal Put Call - newsline.com
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Offers Partial Offset Amid Stock DeclineAnalyst Consensus Shift - newsline.com
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressROA Comparison - newsline.com
BioAtla Inc. (BCAB) Q4 2025 Earnings: EPS Beat Driven by Lower Operating Loss, Stock DeclinesConsensus Beat Rate - dars.gov.et
BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes - Stock Titan
BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineHigh Estimate Range - dars.gov.et
BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Driven by Operational DisciplineEarnings Whisper Number - newsline.com
BioAtla Inc. (BCAB) Slips Nearly 3% as Biotech Sector Faces HeadwindsProfitability Factor - The Legal Advocate
BCAB Q4 2025 Earnings: EPS Surprise and Pipeline Focus Drive Positive SentimentEarnings Outlook Update - newsline.com
BioAtla Inc. (BCAB) Edges Higher as Stock Tests Key Resistance Near $3.95Schiff Line - The Legal Advocate
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentRevenue Surprise History - newsline.com
BCABBioAtla Inc Stock Price and Quote - Finviz
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats EstimatesStrong Earnings Momentum - The Legal Advocate
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):